A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2026-01-15
Target enrollment:
Participant gender:
Summary
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of
comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin
(ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated
A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and
dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)